100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Previously searched by you
Previously searched by you
logo
Antiviral Chemistry & Chemotherapy’s current antiviral agents FactFile (2nd edition): DNA viruses $8.49   Add to cart
Quickly navigate to
Preview
  2.  
  3. Chemistry
  4.  
  5. Chemistry

Exam (elaborations)

Antiviral Chemistry & Chemotherapy’s current antiviral agents FactFile (2nd edition): DNA viruses
 11 views  0 purchase

Antiviral Chemistry & Chemotherapy’s current antiviral agents FactFile (2nd edition): DNA viruses Hugh J Field1 * and Erik De Clercq2 1Department of Veterinary Medicine, University of Cambridge, Cambridge, UK 2Rega Institute for Medical Research, Leuven, Belgium *Corresponding author: E-m...

[Show more]

Preview 2 out of 12  pages

Document information

  • July 26, 2024
  • 12
  • 2023/2024
  • Exam (elaborations)
  • Questions & answers

Subjects

Written for

All documents for this subject (2083)

Seller

avatar-seller
scottgrades

Reviews received

Content preview

© 2008 International Medical Press 51Antiviral Chemistry & Chemotherapy ’s current antiviral agents FactFile (2nd edition): DNA viruses
Hugh J Field1* and Erik De Clercq2 1Department of Veterinary Medicine, University of Cambridge, Cambridge, UK 2Rega Institute for Medical Research, Leuven, Belgium
*Corresponding author: E-mail: AVCCtracker@intmedpress.com
Although most of the recent attempts to develop new antiviral agents have been focussed on RNA viruses (in particular, HIV and hepatitis C virus), a few new c ompounds are now awaiting their entry into the field of DNA v iruses, particularly poxviruses, such as variola virus, because of the bioterrorist context, and herpesviruses, such a s herpes simplex virus and cytomegalovirus, where the market scene has for many years been dominated by acyclovir, pen ciclovir and ganciclovir and their respective orally bioavailable prodrugs: valaciclovir, famciclovir and valganciclo vir. Here, we review the current ‘state of the art’ with old c ompounds ready to rotate off and new compounds eagerly awaiting to appear on the continuously evolving scene of antiviral drug development.
Key to FactFile
StructureSystematic/other names
NotesCompany/Institution
References: xxx,xxxCompound name
Proprietary name
Abbreviation list
BCNA Bicyclic nucleoside analogue CMV cytomegalovirus EBV Epstein–Barr virus FIV feline immunodeficiency virus HBV hepatitis B virus HCMV human cytomegalovirus HHV human herpes virus HPV human papillomavirus HSV herpes simplex virus
NRTI nucleoside reverse transcriptase inhibitorNtRTI nucleotide reverse transcriptase inhibitorSIV simian immunodeficiency virus VZV varicella-zoster virusAntiviral Chemistry & Chemotherapy 19:51–62 Factfile: DNA viruses
© 2008 International Medical Press 52HN
N H2NO
NN
OHO9-(2-Hydroxyethoxymethyl)guanine, acycloguanosine, aciclovir.
Principal target virus : HSV-1, HSV-2, VZV.
Other activities : HCMV, EBV.
Compound class : Acyclic nucleoside analogue.
Clinical stage : Licensed. Patent expired.
The compound is used for the treatment of mucosal, cutaneous and systemic HSV-1 and HSV-2 infections (including HSV encephalitis and genital herpes), an d in VZV infections (including herpes zoster ophthalmicus). It is also used for the prophylaxis of HSV infections (genital herpes) and VZV infections. Extremely safe compound may be used for long-term suppressive therapy. Still regarded as ‘gold standard’ for HSV therapy. Rather poor oral availability; the oral prodrug is valaciclovir.GlaxoSmithKline (GSK)
References: 1–3Acyclovir
Zovirax®
N
NN
N
O PO
HO
OHNH29-[2-(Phosphonylmethoxy)ethyl]adenine, PMEA, GS 393. Principal target virus : HBV.
Other activities : HIV-1, HIV-2, HCMV, HSV-1, HSV-2, FIV, SIV.
Compound class : NtRTI (acyclic nucleoside phosphonate).
Used as its oral prodrug, adefovir dipivoxil, in the treatment of chronic HBV infections.Gilead Sciences
References: 1,4,5Adefovir
N O
N
CH3SN
SNH2
OOCH3N-[5-aminosulfonyl)-4-methyl-1,3-thiazol-2yl)-N-methyl-[4-(2-pyridinyl)
phenyl]acetamide.
Principal target virus : HSV-1, HSV-2.
Mode of action : Inhibits HSV helicase-primase complex. Compound class: Thiazolylsulfonamide
Developed originally by Bayer Company. An extremely active and specific inhibitor of HSV-1 and HSV-2, which has been shown efficacious in a variety of infection models.
Resistance mutations found most frequently in helicase and occasionally in primase genes. Mechanism appears to differ slightly from BILS 22BS.AiCuris
References: 6–8BAY 57-1293

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller scottgrades. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $8.49. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

76462 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$8.49
  • (0)
  Add to cart